Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate Safety and Immunogenicity of GSK Biologicals' Pandemic Influenza (H1N1) Candidate Vaccine in Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~All subjects must satisfy ALL the following criteria at study entry:~* Subjects who the investigator believes that their parent(s)/Legally Acceptable Representative(s) (LARs) can and will comply with the requirements of the protocol~* Children, male or female, aged between 8 and 12 weeks at the time of first study vaccination.~* Written informed consent obtained from the parent(s)/LAR(s) of the subject.~* Healthy children, as established by medical history and clinical examination when entering the study.~* Parent/LAR with access to a consistent means of telephone contact, land line or mobile, but NOT a pay phone or other multiple-user device.~* Born after a gestation period of \>= 36 to \<= 42 weeks.~Exclusion Criteria:~The following criteria should be checked at the time of study entry. If ANY exclusion criterion applies, the subject must not be included in the study:~* Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine within 30 days preceding the first dose of the study vaccine or planned use during the study period.~* Acute disease at the time of enrolment.~* Any confirmed or suspected immunosuppressive or immunodeficient condition based on medical history and physical examination (no laboratory testing required).~* History of any neurological disorders or seizures.~* A family history of congenital or hereditary immunodeficiency.~* Receipt of systemic glucocorticoids within one month of study enrolment, or any other cytotoxic or immunosuppressive drug since birth.~* Administration of any vaccines within two weeks before study enrolment.~* Administration of immunoglobulins and/or any blood products since birth or planned administration during the study.~* Previous administration of any H1N1 vaccine, of any seasonal influenza vaccine.~* Previous vaccination against diphtheria, tetanus, pertussis, poliomyelitis, Haemophilus influenzae type b, and/or Streptococcus pneumoniae with the exception of vaccines where the first dose can be given within the first two weeks of life according to the national recommendations.~* History of intercurrent diphtheria, tetanus, pertussis, poliomyelitis, Haemophilus influenzae type b disease.~* Major congenital defects or serious chronic illness.~* Child in care.~* Any known or suspected allergy to any constituent of the influenza, DTPa-IPV/Hib and pneumococcal study vaccines; a history of anaphylactic-type reaction to consumption of eggs; or a history of severe adverse reaction to a previous influenza, DTPa-IPV/Hib and pneumococcal vaccine.

- Gender: ALL
- Minimum Age: 8 Weeks
- Maximum Age: 12 Weeks
- Healthy Volunteers: t

Study Arms:
- GSK2340272A Group 1 (Type: EXPERIMENTAL): Healthy male or female children, between and including 8 and 12 weeks of age at the time of first vaccination, received 2 primary doses of GSK2340272A vaccine, according to a 0-28 day schedule. Subjects also received routine infant immunisation (Infanrix™-IPV/Hib) and Prevenar™ vaccine at Day 14, Month 3 and Month 10. All vaccines were administered intramuscularly into the anterolateral region of the thigh.
- GSK2340272A Group 2 (Type: EXPERIMENTAL): Healthy male or female children, between and including 8 and 12 weeks of age at the time of first vaccination, received 2 primary doses of GSK2340272A vaccine, according to a 0-4 month schedule. Subjects also received routine infant immunisation (Infanrix™-IPV/Hib) and Prevenar™ vaccine at Day 14, Month 3 and Month 10. All vaccines were administered intramuscularly into the anterolateral region of the thigh.

Based on this trial design, predict the completion outcome and termination type (if applicable).